Roger Goldberg, MD
Retina Specialist · Walnut Creek, CANPI 1184866584
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 24.5% of the total. 2025 is the largest year on record at $221,358, 2.0 times the $110,447 reported in 2019. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 824 payments — averaging $1274.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$257K
- Genentech USA, Inc.$191K
- Boehringer Ingelheim International GmbH$125K
- AbbVie$75K
- Novartis$64K
- Regeneron Healthcare Solutions, Inc.$56K
- plus $281K from 30 others
Across 1,024 payments — averaging $3855.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche TCRC, Inc.$1.5M
- Genentech, Inc.$870K
- Apellis Pharmaceuticals, Inc.$515K
- Boehringer Ingelheim$357K
- Eyepoint US, Inc.$213K
- Janssen Research & Development, LLC$135K
- plus $370K from 9 others
What the payments were for
- Consulting fees$551,91353%
- Speaking & faculty fees$380,14036%
- Travel & lodging$101,07510%
- Food & beverage$16,3452%
- Education$4360%
- Gifts$1500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$150,216
- VABYSMO$148,178
- EYLEA$54,869
- Lucentis$51,984
- OZURDEX$46,812
- ENCELTO$40,634
- EYLEA HD$34,071
- BEOVU$21,445
- EYP-1901$19,886
- Clarus 700$11,850
- CIRRUS HD-OCT$11,650
- Non-Covered Product$7,434
- YUTIQ$4,652
- FORUM$3,750
- CLARUS$3,700
- Iluvien$3,637
- CLARUS 500$3,600
- Retina Workplace$2,720
- Humphrey HFA$2,580
- CIRRUS 5000$2,400
How this compares
$1,050,058 in reported general payments places this provider in the 95th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 86 | $4,456 |
| MoxifloxacinMoxifloxacin Hcl | 51 | $1,158 |
| Brimonidine Tartrate | 15 | $900 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 52 | $540 |
| Latanoprost | 27 | $352 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Walnut Creek
- Caesar LuoWalnut Creek$294K
- Subhransu RayWalnut Creek$16K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Baruch KuppermannIrvine$1M
- Carlos Medina MendezSacramento$548K
- Michael JavaheriBeverly Hills$540K
- Esther KimSanta Ana$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.